Literature DB >> 15471895

Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice.

Stacy A Blaine1, Amy M Meyer, Greg Hurteau, Marilee Wick, Joseph A Hankin, Robert C Murphy, Andrew J Dannenberg, Mark W Geraci, Kotha Subbaramaiah, Raphael A Nemenoff.   

Abstract

There is a significant body of evidence suggesting that enzymes involved in arachidonic acid metabolism and their eicosanoid products play a role in various cancers, having both pro- and antitumorigenic effects. The goal of this study was to further define the role microsomal prostaglandin E synthases (mPGES-1) play in lung tumorigenesis. Transgenic mice were created with targeted over-expression of human mPGES-1 in the alveolar and airway epithelial cells using an SP-C promoter driven construct. Transgene positive (mPGES-1+) mice were shown to significantly over-express functional mPGES-1 in the lung and more specifically in alveolar type II cells. To study the effects of mPGES-1 over-expression in lung tumor formation, mice were exposed to a complete carcinogen protocol with a single injection of urethane or an initiation/promotion model with a single injection of 3-methylcholanthrene (MCA) followed by multiple injections of butylated hydroxytoluene (BHT). mPGES-1+ mice did not show a significant difference in tumor multiplicity or tumor size at 10, 16, 19 or 30 weeks after urethane injection compared with mPGES-1- mice. No significant difference was seen in tumor incidence, multiplicity or size at 19 weeks after treatment with MCA/BHT. Western blots verified that mPGES-1 expression was increased in tumors versus uninvolved tissue of both mPGES-1+ and mPGES-1- mice with overall expression being significantly higher in mPGES-1+ mice. Cyclooxygenase-2 levels were elevated in tumors in both groups. From these studies we conclude that over-expression of mPGES-1 and highly elevated PGE2 production are not sufficient to induce lung tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471895     DOI: 10.1093/carcin/bgh302

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  5 in total

1.  Oral iloprost improves endobronchial dysplasia in former smokers.

Authors:  Robert L Keith; Patrick J Blatchford; John Kittelson; John D Minna; Karen Kelly; Pierre P Massion; Wilbur A Franklin; Jenny Mao; David O Wilson; Daniel T Merrick; Fred R Hirsch; Timothy C Kennedy; Paul A Bunn; Mark W Geraci; York E Miller
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Cyclooxygenase-1 overexpression decreases Basal airway responsiveness but not allergic inflammation.

Authors:  Jeffrey W Card; Michelle A Carey; J Alyce Bradbury; Joan P Graves; Fred B Lih; Michael P Moorman; Daniel L Morgan; Laura M DeGraff; Yun Zhao; Julie F Foley; Darryl C Zeldin
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

3.  Ceramide 1-phosphate is required for the translocation of group IVA cytosolic phospholipase A2 and prostaglandin synthesis.

Authors:  Nadia F Lamour; Preeti Subramanian; Dayanjan S Wijesinghe; Robert V Stahelin; Joseph V Bonventre; Charles E Chalfant
Journal:  J Biol Chem       Date:  2009-07-23       Impact factor: 5.157

4.  Foxm1 transcription factor is required for macrophage migration during lung inflammation and tumor formation.

Authors:  D Balli; X Ren; F-S Chou; E Cross; Y Zhang; V V Kalinichenko; T V Kalin
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

5.  Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis.

Authors:  I-Ching Wang; Lucille Meliton; Xiaomeng Ren; Yufang Zhang; David Balli; Jonathan Snyder; Jeffrey A Whitsett; Vladimir V Kalinichenko; Tanya V Kalin
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.